Обычный вид

Появились новые статьи. Нажмите, чтобы обновить страницу.
Сегодня — 5 мая 2026EnRSS

Bolsonaro discharged from hospital following shoulder surgery

Logo Agência Brasil

Former President Jair Bolsonaro was discharged from the hospital on Monday afternoon (May 4) after undergoing shoulder surgery to treat an injury to his right rotator cuff.

He had been hospitalized at the DF Star Hospital in Brasília since last Friday (May 1).

Notícias relacionadas:

The operation went smoothly, and the former president showed good clinical progress, according to a statement from the hospital.

Jair Bolsonaro’s surgery was an arthroscopic repair of the rotator cuff to treat injuries confirmed by imaging tests and a physical therapy report. The procedure was authorized by Supreme Court Justice Alexandre de Moraes, following a favorable opinion from Attorney General Paulo Gonet.

Bolsonaro, 71, has been under humanitarian house arrest since March 24, following a decision by Alexandre de Moraes after he was hospitalized for bacterial pneumonia. The former president was sentenced by the First Panel of the Supreme Court in September 2025 to 27 years and 3 months in prison for his leading role in the coup plot.

Brazil to produce chikungunya vaccine

5 мая 2026 в 16:47

Logo Agência Brasil

Brazil’s national drug regulator, Anvisa, on Monday (May 4), authorized the Butantan Institute to manufacture the chikungunya vaccine, Butantan-Chik.

With this authorization, the vaccine can now be incorporated into the country’s public healthcare network, the SUS. It is indicated for people aged 18 to 59 who have been exposed to the virus.

Notícias relacionadas:

Following this authorization, the Butantan Institute has also been officially designated as a manufacturing site. The vaccine was approved by the regulatory agency in April 2025, but the registered production sites were the facilities of the Franco-Austrian pharmaceutical company Valneva. It will now be produced (formulated and bottled) in Brazil with the same quality, safety, and efficacy, according to the São Paulo state government.

“This is another important milestone for the Butantan Institute and for public health. By carrying out most of the manufacturing process, the institute, as a public institution, will be able to deliver the vaccine at a lower, more affordable price, with the same quality and safety,” said the institute’s director, Esper Kallás.

At least 4,000 volunteers, aged 18 to 65, received the vaccine in the United States and were evaluated. According to results published in the medical journal The Lancet in 2023, 98.9 percent of participants produced neutralizing antibodies.

The vaccine was well tolerated and showed a favorable safety profile, with adverse events that were generally mild to moderate, most commonly headache, body aches, fatigue, and fever.

In February 2026, the vaccine began to be administered through the SUS in municipalities with high disease incidence, as part of a pilot strategy by the Ministry of Health. In addition to Brazil, the chikungunya vaccine has been approved in Canada and Europe.

Chikungunya

The chikungunya virus is transmitted by the bite of the Aedes aegypti mosquito, which also transmits dengue and Zika.

The disease can cause sudden-onset fever (above 38.5°C) and severe pain in the joints of the feet and hands - such as the fingers, ankles, and wrists. Other common symptoms include headache, muscle pain, and red spots on the skin.

According to the Pan American Health Organization, 500,000 cases of chikungunya were reported worldwide in 2025.

In Brazil, more than 127,000 cases and 125 deaths were reported in the same year, according to the Ministry of Health.

The disease causes chronic joint pain, which can last for months to years and severely affect quality of life.

❌
❌